No, the mechanisms are too completely unrelated. In the far future, an anti-telomerase drug and a JAK inhibitor drug might be alternative approaches considered comparably, with the one not chosen first as a backup.
The fact, that they work so differently, could mean that they complement each other. I wonder if this was tried at Mayo, since they have access to both drugs. It seems that the blood cancer patient has new hope.